Taysha Gene Therapies, Inc.
TSHA
$1.24
$0.065.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 13.09% | 60.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.09% | 60.79% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 13.09% | 60.79% | |||
| SG&A Expenses | -54.17% | 7.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.91% | 1.95% | |||
| Operating Income | 5.36% | 1.12% | |||
| Income Before Tax | 26.40% | -21.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 26.40% | -21.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 26.40% | -21.96% | |||
| EBIT | 5.36% | 1.12% | |||
| EBITDA | 5.48% | 1.01% | |||
| EPS Basic | 26.55% | -6.01% | |||
| Normalized Basic EPS | 9.52% | 8.35% | |||
| EPS Diluted | 26.55% | -6.01% | |||
| Normalized Diluted EPS | 9.52% | 8.35% | |||
| Average Basic Shares Outstanding | 0.21% | 15.03% | |||
| Average Diluted Shares Outstanding | 0.21% | 15.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||